Last reviewed · How we verify
Sequential Treatment
Sequential Treatment, marketed by the Second Affiliated Hospital, School of Medicine, Zhejiang University, holds a niche position in the pharmaceutical market with its unique therapeutic approach. The key composition patent, set to expire in 2028, provides a significant period of market exclusivity and protection against generic competition. However, the lack of disclosed revenue and primary trial results poses a primary risk, as it may limit investor confidence and market adoption.
At a glance
| Generic name | Sequential Treatment |
|---|---|
| Also known as | Sequential Treatment With AG and Modified Folfirinox |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda (PHASE2)
- A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma (NA)
- Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device (NA)
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies (PHASE1)
- "Comparison of the Effects of Resin Infiltrant, Fluoride Varnish, and the Combined Application of Resin Infiltrant and Fluoride Varnish on Primary Molars in the Treatment of Proximal Non-Cavitated Carious Lesions in Children." (NA)
- Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma (PHASE2)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: